Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Jia Ruan(Cornell University), John P. Leonard(New York University), Peter Martin(Northwestern University), Ethel Cesarman(Cornell University), Amy Chadburn(Cornell University), Rebecca Elstrom(Acentech (United States)), Julie M. Vose(University of Nebraska Medical Center), Morton Coleman(Cornell University), Scott Ely(NewYork–Presbyterian Hospital), Ann S. LaCasce(Otsuka (Japan)), J. Kaitlin Morrison(NewYork–Presbyterian Hospital), Richard R. Furman(Cornell University), Ken Cheung(Columbia University), Shing M. Lee(Columbia University)
Cited by 319
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k